Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia

Seminars in Nuclear Medicine

Volumn 33, Issue 1, 2003, Pages 77-85

  Van Heertum, Ronald L ^a,b   Tikofsky, Ronald S ^a,b,c  

^a Coll Phys/Surgs of Columbia Univ ^*  (United States)

^b HARLEM HOSPITAL CENTER   (United States)

^c Harkness Pavilion ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUORODEOXYGLUCOSE; GALANTAMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BRAIN FUNCTION; BRAIN SCINTISCANNING; CHOLINESTERASE INHIBITION; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FUTUROLOGY; HUMAN; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; RECEPTOR DENSITY; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0037258406     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2003.127294     Document Type: Review

References (58)

1. Alzheimer A: Uber eine eigenartige Erkankung der Hirnirinde. Allegmeine Z Psychiatr 64:146-148, 1907
2. Hy LX, Keller DM: Prevalence of AD among whites: A summary by levels of severity. Neurology 55:198-204, 2000
3. Albert MS, Drachman DA: Alzheimer's disease: What is it, how many people have it, and why do we need to know? Neurology 56:166-168, 2000
4. Witthaus E, Ott A, Barendregt JJ, et al: Burden of mortality and morbidity from dementia. Alzheimer Dis Assoc Disord 3:176-181, 1999
5. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: Report on NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-942, 1989
6. Wetterling T, Kanitz RD, Borgis KJ: Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 27:30-36, 1996
7. Practice parameter for diagnosis and evaluation of dementia (summary statement). Report of the Quality Standards Subcommittee of American Academy of Neurology. Neurology 44:2203-2206, 1994
8. Practice parameter: Early detection of dementia - Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 6:1133-1142, 2001
9. Van Heertum RL, Tikofsky RS, Rubens AB: Dementia, in Van Heertum RL, Tikofsky RS (eds): Functional Cerebral SPECT and PET Imaging (ed 3). New York, NY, Lippincott Williams & Wilkins, 2000, pp 127-188
10. Corder EH, Saunders AM, Strittmatter WJ, et al: Gene dose of apolipoprotein E type 4 and the risk of Alzheimer's disease in late onset families. Science 261:921-923, 1993
11. Corder EH, Saunders AM, Risch NJ, et al: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180-184, 1994
12. Strittmatter WJ, Saunder AM, Schmechel D, et al: Apoliprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. PNAS 90:1977-1981, 1993
13. De Leon MJ, Convit A, Wolf OT, et al: Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 98:10966-10971, 2001
14. Small GW, Ercoli LM, Silverman DHS, et al: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97:6037-6042, 2000
15. Arnaiz E, Jelic V, Almkvist O, et al: Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12:851-855, 2001
16. De Santi S, de Leon MJ, Rusinek H, et al: Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22:529-539, 2001
17. Tanaka M, Fukuyama H, Yamauchi H, et al: Regional cerebral blood flow abnormalities in nondemented patients with memory impairment. J Neuroimaging 12:112-118, 2002
18. Silverman DHS, Gmbhir SS, Huang H-WC, et al: Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits. J Nucl Med 43:253-266, 2002
19. Hokoishi K, Ikeda M, Maki N, et al: Frontotemporal lobar degeneration: A study in Japan. Dement Geriatr Cogn Disord 2:393-399, 2001
20. Pawlik G, Heiss WD: Positron emission tomography and neuropsychological function, in Bigler ED, Yeo RA, Turkheimer E (eds): Neuropsychological Function and Brain Imaging, chap 4. New York, NY, Plenum Press, 1989, pp 65-138
21. Tikofsky RS, Hellman RS, Parks RW: Single photon emission computed tomography and applications to dementia, in Parks RW, Zec RF, Wilson RS (eds): Neuropsychology of Alzheimer's Disease and Other Dementias. New York, NY, Oxford University Press, 1993, pp 489-510
22. Hellman RS, Tikofsky RS, Van Heertum RL, et al: A multi-institutional study of interobserver agreement in the evaluation of dementia with rCBF/SPECT technetium-99m exametazime (HMPAO). Eur J Nucl Med 21:306-313, 1994
23. Mayberg H: Clinical correlates of PET and SPECT-identified defects in dementia. J Clin Psychiatry 55:12-21, 1994 (suppl)
24. Sabri O, Schneider R, Buell U: Comparison of PET, SPET, neuropsychological and morphological findings in vascular dementia. Eur J Nucl Med 24:348-349, 1997
25. Talbot PR, Snowden JS, Lloyd JJ, et al: The contribution of single photon emission tomography to the clinical differentiation of degenerative cortical brain disorders. J Neurol 242:579-586, 1995
26. Varma AR, Adams W, Lloyd LL, et al: Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 05:261-269, 2002
27. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47:1113-1124, 1996
28. 123I-beta-CIT singlephoton emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 24:320-325, 1997
29. Ishii K, Yamaji S, Kitagaki H, et al: Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 53:413-416, 1999
30. 18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 25:447-456, 2001
31. Ishii K, Imamura T, Sasaki M, et al: Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 51:125-130, 1998
32. Mori E, Ishii K, Hashimoto M, et al: Role of functional brain imaging in the evaluation of vascular dementia. Alzheimer Dis Assoc Disord 24:S91-101 (suppl 3), 1999
33. Lass P, Buscombe JR, Harber M, et al: Cognitive impairment in patients with renal failure is associated with multiple-infarct dementia. Clin Nucl Med 24:561-565, 1999
34. De Reuck J, Siau B, Decoo D, et al: Parkinsonism in patients with vascular dementia: Clinical, computed- and positron emission-tomographic findings. Cerebrovasc Dis 11:51-58, 2001
35. Tohgi H, Chiba K, Sasaki K, et al: Cerebral perfusion patterns in vascular dementia of the Binswanger type compared with senile dementia of Alzheimer type: A SPECT study. J Neurol 238:365-370, 1991
36. 99mTc-HMPAO SPECT study. Eur J Nucl Med 23:1338-1344, 1996
37. Tohgi H, Yonezawa H, Takahashi S, et al: Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology 40:131-137, 1998
38. Nagata K, Maruya H, Yuya H, et al: Can PET data differentiate Alzheimer's disease from vascular dementia? Ann N Y Acad Sci 903:252-261, 2000
39. De Reuck J, Santens P, Strijckmans K, et al: Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. J Neurol Sci 193:1-6, 2001
40. 99mTc-HMPAO and the acetazolamide test in the evaluation of vascular and Alzheimer's dementia. Eur J Nucl Med 26:239-245, 1999
41. Duara R, Baker W, Luis CA: Frontotemporal dementia and Alzheimer's disease: Differential diagnosis. Dement Geriatr Cogn Disord 10:37-42, 1999 (suppl 1)
42. Miller BL, Gearhart R: Neuroimaging in the diagnosis of frontotemporal dementia. Dement Geriatr Cogn Disord 10:71-74, 1999 (suppl 1)
43. Sjogren M, Gustafson L, Wikkelso C, et al: Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior-to-posterior rCBF SPET ratio. Dement Geriatr Cogn Disord 11:275-285, 2000
44. Charpentier P, Lavenu I, Defebvre L, et al: Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data. J Neurol Neurosurg Psychiatry 69:661-663, 2000
45. Pagani M, Salmaso D, Ramstrom C, et al: Mapping pathological (99m) Tc-d,I-hexamethylpropylene amine oxime uptake in Alzheimer's disease and frontal lobe dementia with SPECT. Dement Geriatr Cogn Disord 12:177-184, 2001
46. Hodges JR: Frontotemporal dementia (Pick's disease): Clinical features and assessment. Neurology 56:S6-10, 2001 (11 suppl 4)
47. Mummery CJ, Patterson K, Wise RJS, et al: Disrupted temporal lobe connections in semantic dementia. Brain 122:61-73, 1999
48. Grossman M, Payer F, Onishi K, et al: Language comprehension and regional cerebral defects in frontotemporal degeneration and Alzheimer's disease. Neurology 50:57-63, 1998
49. San Pedro EC, Deutsch G, Liu HG, et al: Frontotemporal decreases in rCBF correlate with degree of dysnomia in primary progressive aphasia. J Nucl Med 41:228-233, 2000
50. Pal PK, Wszolek ZK, Kishore A, et al: Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation tau gene). Parkinsonism Relat Disord 7:81-88, 2001
51. Martin JA, Craft DK, Su JH, et al: Astrocytes degenerate in frontotemporal dementia: Possible relation to hypoperfusion. Neurobiol Aging 22:195-207, 2002
52. Jauss M, Herholz K, Kracht L, et al: Frontotemporal dementia: Clinical, neuroimaging, and molecular biological findings in 6 patients. Eur Arch Psychiatry Clin Neurosci 251:225-231, 2001
53. Rinne JO, Laine M, Kaasinen V, et al: Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 58:1489-1493, 2002
54. Holman BL, Garada B, Johnson KA, et al: A comparison of brain perfusion SPECT in cocaine abuse and AIDS dementia complex. J Nucl Med 33:1312-1315, 1992
55. Kim DM, Tien R, Byrum C, et al: Imaging in acquired immune deficiency syndrome dementia complex (AIDS dementia complex): A review. Prog Neuropsychopharmacol Biol Psychiatry 20:349-370, 1996
56. Sacktor N, Prohovnik I, Van Heertum RL, et al: Cerebral singlephoton emission computed tomography abnormalities in human immunodeficiency virus type 1-infected gay men without cognitive impairment. Arch Neurol 52:607-611, 1995
57. Szeto ER, Freund J, Brew BJ, et al: Cerebral perfusion scanning in treating AIDS dementia: A pilot study. J Nucl Med 39:298-302, 1998
58. 99mTc-HMPAO in subjects with HIV infection: Cognitive dysfunction correlates with high uptake. Scand J Infect Dis 31:349-354, 1999